GTx-104: The 40-Year Wait

On Wednesday, April 23, the FDA will decide whether to approve GTx-104 — an IV formulation of nimodipine for aneurysmal subarachnoid hemorrhage. If approved, it will be the first new treatment option for aSAH patients in 40 years.

Today at AAN in Chicago, Grace Therapeutics presented the STRIVE-ON Phase 3 data. GRCE closed up 8.38%. The PDUFA is in two days.

This is what the FDA is looking at.

The Problem

Aneurysmal subarachnoid hemorrhage kills roughly 50% of patients. Those who survive often face severe disability. The standard of care — oral nimodipine — was approved in 1988. It hasn't changed since.

The drug works. The delivery doesn't. Oral nimodipine requires patients to swallow capsules every four hours, around the clock. But aSAH patients are often unconscious, intubated, or dysphagic. So clinicians crush capsules, extract liquid with syringes, and push it through nasogastric tubes — an off-label workaround that introduces dosing errors, aspiration risk, and hypotension from erratic absorption.

What GTx-104 Is

GTx-104 is IV nimodipine. Same molecule, different route. Grace Therapeutics used nanoparticle technology to make insoluble nimodipine water-compatible for standard peripheral IV infusion. No nasogastric tube. No syringe extraction. No food-effect variability. Continuous, controlled delivery in the ICU setting where these patients already are.

It has Orphan Drug Designation, which grants 7 years of marketing exclusivity if approved.

STRIVE-ON: The Phase 3 Data

The pivotal STRIVE-ON trial (NCT05995405) randomized 102 aSAH patients: 50 to GTx-104, 52 to oral nimodipine. Prospective, randomized, open-label. Today's AAN poster — Session S21, 1 PM CT — presented the full results.

The dose compliance number is the headline. Only 8% of oral nimodipine patients achieved ≥95% relative dose intensity. With GTx-104, 54% did. That's the difference between the theoretical treatment and the actual treatment — the drug patients are supposed to get versus the drug they actually receive.

The Regulatory Read

This is a 505(b)(2) NDA — meaning Grace is referencing the existing safety/efficacy data for nimodipine (established over 40 years) and demonstrating that GTx-104 delivers the same drug with a better safety profile via a more reliable route. The FDA doesn't need to be convinced nimodipine works. They need to be convinced GTx-104 delivers it safely and consistently.

STRIVE-ON answers that directly: less hypotension, dramatically better compliance, fewer ICU readmissions, no new safety signals. The trial wasn't designed to prove superiority on efficacy — it was designed to prove the delivery is better. It did.

Context: Post-Pazdur FDA

The FDA under its new oncology leadership has been stricter. RP1 (Replimune) received a second Complete Response Letter on April 10 — efficacy concerns that additional analyses "did not alter." But GTx-104 isn't an oncology candidate, and it's not asking the FDA to accept a novel mechanism. It's asking the FDA to approve a better delivery of a drug that's been standard of care for four decades. Different regulatory conversation entirely.

No advisory committee was convened. For NDAs, the absence of an adcom is generally a positive signal — it suggests the FDA didn't see enough uncertainty to warrant external expert review.

The Numbers

Wednesday

The PDUFA date is April 23. The FDA typically acts on or before the target date. Grace Therapeutics has been engaged in pre-commercial planning.

This isn't a blockbuster drug candidate. It's a clinical workflow fix for a devastating condition that hasn't seen innovation in a generation. The question isn't whether nimodipine works — that was settled in the 1980s. The question is whether the FDA agrees that ICU patients deserve a way to actually receive it.

Ticker: GRCE (Nasdaq) · PDUFA: April 23, 2026 · Designation: Orphan Drug · NDA type: 505(b)(2)